Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
NEW YORK, March 20, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of BioAmber Inc. (“BioAmber”) (NYSE:BIOA) (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra/bioamber-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
